地舒单抗对比唑来膦酸对新诊断多发性骨髓瘤无进展生存期的探索性分析
该研究为国际3期试验的探索性分析,在新诊断多发性骨髓瘤患者中比较地舒单抗与唑来膦酸对无进展生存期(PFS)的影响。结果显示地舒单抗组中位PFS延长10.7个月,获益在计划接受自体干细胞移植(ASCT)及接受蛋白酶体抑制剂为基础的三联诱导方案患者中最显著。
要点
- 地舒单抗较唑来膦酸延长中位PFS 10.7个月。
- 计划ASCT且接受三联诱导者PFS获益最强(HR 0.65)。
- 不计划ASCT者未见PFS获益。
核心结论
- 地舒单抗对比唑来膦酸在新诊断多发性骨髓瘤中显示PFS获益,尤其在计划ASCT和接受PI为基础三联诱导的患者中。
研究设计与样本
- 国际3期试验的探索性分析,纳入1718例新诊断多发性骨髓瘤患者。
- 按ASCT意向、年龄(<70或≥70岁)和基线肾功能(CrCl≤60或>60 mL/min)进行亚组分析。
主要发现
- 930例(54.1%)为ASCT意向组,788例(45.9%)为无ASCT意向组。
- 无ASCT意向组中未观察到地舒单抗对比唑来膦酸的PFS获益。
- CrCl>60 mL/min和<70岁患者中PFS favoring地舒单抗,而CrCl≤60 mL/min或≥70岁患者中无差异。
临床怎么用
- 对于计划接受ASCT并接受PI为基础三联诱导的新诊断多发性骨髓瘤患者,地舒单抗可能带来PFS获益。
局限性
- 本研究为探索性分析,P值为描述性,需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
An exploratory end point from a recent trial in patients with newly diagnosed multiple myeloma showed that median progression-free survival (PFS) was increased by 10.7 months with denosumab vs zoledronic acid. We performed additional analyses to identify factors that may have contributed to the favorable PFS with denosumab. Ad hoc analyses were performed for patients intending to undergo autologous stem cell transplantation (ASCT; ASCT intent), not intending to undergo ASCT (ASCT no intent), and intent-to-treat according to age (<70 or ≥70 years) and baseline renal function (≤60 mL/min or >60 mL/min creatinine clearance [CrCl]). Of 1718 patients, 930 (54.1%) were in the ASCT-intent subgroup, and 788 (45.9%) were in the ASCT-no-intent subgroup. In the ASCT-intent subgroup, frontline triplet (median PFS, not estimable vs 35.7 months; hazard ratio [HR] [95% confidence interval (CI)], 0.65 [0.47-0.90]; descriptive P = .009) or bortezomib-only (median PFS, not estimable vs not estimable; HR [95% CI], 0.61 [0.39-0.95]; descriptive P = .029) induction regimens demonstrated the strongest PFS benefit favoring denosumab vs zoledronic acid. In the ASCT-no-intent subgroup, no benefit with denosumab vs zoledronic acid was observed. PFS favored denosumab vs zoledronic acid in patients with CrCl >60 mL/min and in patients <70 years old, but no difference was observed in patients with CrCl ≤60 mL/min or patients ≥70 years old. The PFS difference observed with denosumab is one of the notable benefits reported in newly diagnosed multiple myeloma and was most pronounced in patients intending to undergo ASCT and those who received proteasome inhibitor (PI)-based triplet regimens. This study was registered at www.clinicaltrials.gov as #NCT01345019.
引用
- Terpos E, Raje N, Croucher P, et al. Denosumab compared with zoledronic acid on PFS in multiple myeloma: exploratory results of an international phase 3 study. Blood Adv. 2021. PMID: 33560384. doi:10.1182/bloodadvances.2020002378
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。